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Background and study aims: The eradication rate of Helicobacter pylori (H. pylori) has been reported as
being lower in patients with type 2 diabetes mellitus (DM) than in those without DM. The aim of the
study was to assess the efﬁcacy of the two H. pylori eradication regimens in patients without and with
type 2 DM and to study the effect of H. pylori treatment on glycaemia control.
Patients and Methods: A total of 93 consecutive type 2 DM (non-insulin users) and 98 non-diabetic age-
and sex-matched patients were enrolled. Patients were randomly assigned to one of the two treatment
protocols all given twice daily: (a) a 14-day quadruple therapy comprising of omeprazole 20 mg, metro-
nidazole 500 mg, amoxicillin 1 g and bismuth subcitrate 240 mg (OMAB) and (b) a 14-day triple regimen
comprising of omeprazole 20 mg plus clarithromycin 500 mg and amoxicillin 1 g (OCA). Cure was deﬁned
as a negative 13C-urea breath test at least 6 weeks after treatment.
Results: The H. pylori eradication rate with the OCA regimen was 63% in patients with type 2 DM (non-
insulin users) and 87.7% in the control group (p = 0.017). The H. pylori eradication rate with the OMAB
regimen was 38.2% in patients with type 2 DM and 55.1% in the control group (p < 0.001). Mean decrease
of fasting plasma glucose and HbA1c level shows no statistically signiﬁcant difference after H. pylori erad-
ication.
Conclusion: This study suggests that the eradication rate of H. pylori with OCA or OMAB treatment is
lower in patients with type 2 diabetes than in non-diabetics and H. pylori treatment in patients with type
2 DM has no role in the control of the glycaemia. The triple therapy (OCA) is superior to the quadruple
protocol (OMAB) in H. pylori eradication of both DM and non-DM cases.
 2013 Arab Journal of Gastroenterology. Published by Elsevier B.V. All rights reserved.Introduction
Diabetes mellitus (DM) is one of the most prevalent endocrine
diseases and the importance of glycaemia control has been empha-
sised by studies showing that diabetic patients with higher levels
of glycosylated haemoglobin (HbA1c) have more complications
such as retinopathy, nephropathy and neuropathy [1]. Infections
can lead to hyperglycaemia in patients with DM because the in-
creased production of cytokines can stimulate the secretion of
insulin counter-regulatory hormones [2]. Infection with Helicobac-
ter pylori (H. pylori) induces gastric inﬂammation and has been
associated with an increased production of cytokines such as tu-
mour necrosis factor, interferon-c and interleukins. The patients
with concomitant H. pylori infection require higher doses of insulin
and yet had higher levels of HbA1c than their uninfected counter-
parts [3].f Gastroenterology. Published by El
.
edmajidi).Type 2 DM can present with many gastrointestinal symptoms
and H. pylori can play a role in these diseases [4]. Xia et al. showed
that the seroprevalance of H. pylori infection was not statistically
different in patients with DM and non-diabetic controls [5]. This
prevalence should be corrected for age and gender and there are
no differences if an adjustment has been done [6]. Further, the
eradication of H. pylori shows great differences between different
ethnic groups and in patients with some chronic conditions [4].
Selection of the best drug regimens for effective eradication ofH.
pylori infection, especially in patients at risk of peptic-ulcer relapses,
is already challenging. Nowadays, quadruple therapy has been pro-
duced as an effective drug regimen and even an alternative ﬁrst-line
treatment for eradicating H. pylori infection, especially in areas of
high prevalence of antibiotic resistance [7]. Some recent studies
have suggested that the effectiveness, compliance and side effects
of quadruple regimen containing a gastric-acid inhibitor, a bismuth
compound and amoxicillin might be comparable with proton-
pump-inhibitor (PPI)-based triple therapy when administered as
ﬁrst-line treatment for H. pylori infection [8–11]. However, somesevier B.V. All rights reserved.
Table 1
Baseline characteristics of study subjects in different groups.
Character Groups Total (n = 191) p value
DM + OMAB (n = 47) DM + OCA (n = 46) Control + OMAB (n = 49) Control + OCA (n = 49)
Age (years) 55.5 ± 10.6 55.1 ± 10.3 56.1 ± 9.7 55.6 ± 8.9 55.6 ± 9.8 0.23
Gender (M/F) 25/22 25/21 26/23 27/22 103/88 0.89
BMI (kg m2) 27.9 ± 3.7 27.9 ± 3.5 27.4 ± 3.3 27.1 ± 3.9 27.5 ± 3.6 0.23
HbA1c (%) 9.5 ± 1.6 9.4 ± 1.7 – – – 0.57
Fasting Plasma Glucose (mg dl1) 135.6 ± 37.5 135.6 ± 38.6 – – – 0.66
OMAB = omeprazole, metronidazole, amoxicillin and bismuth subcitrate.
OCA = omeprazole, clarithromycin and amoxicillin.
HbA1c = glycosylated haemoglobin.
DM = diabetes mellitus.
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vour of quadruple therapy [12,13].
Therefore, the advantages of quadruple therapy at present do
not seem clear enough to change the current policies for H. pylori
treatment. Further, the effect of prolonging the duration of quadru-
ple therapy on treatment efﬁcacy is already questioned. The pri-
mary aim of the study was to assess and compare the efﬁcacy of
the two H. pylori eradication regimens in patients without and with
type 2 DM in the Iranian population. The secondary aim was to
study the effect of H. pylori treatment on glycaemia control in dia-
betic patients.
Patients and methods
A prospective double-blinded, randomised clinical trial was
conducted on 100 consecutive type 2 DM (non-insulin users) pa-
tients and 100 non-diabetic age- and sex-matched control patients
with upper gastrointestinal symptoms between March 2009 and
April 2011. All patients signed an informed consent form. This re-
search was approved by the Ethics Committee of Research Center
for Gastroenterology and Liver Disease at Shahid Beheshti Univer-
sity of Medical Sciences.
Patients had not been previously treated for H. pylori infection.
Subjects were excluded if they had been taking non-steroidal anti-
inﬂammatory drugs (NSAIDs), PPIs, bismuth preparations or anti-
biotics during the previous 8 weeks. Pregnant women and patients
with a history of smoking, alcohol consumption, abdominal sur-
gery, drug allergy, renal failure and hepatic impairment were not
enrolled. Dyspepsia was deﬁned as epigastric pain or discomfort
lasting for at least 3 months. Patients with type 2 DM with previ-
ously diagnosed gastroparesis were excluded from the study. All
patients were diagnosed to be H. pylori positive by histopatholo-
gical examination. Gastroscopy was done using a video scopeTable 2
Upper GI endoscopic ﬁndings of study subjects in different groups.
Character Group
DM + OMAB (n = 47) DM + OCA (n = 46) Control +
Gastritis
Normal 22 (46.8%) 21 (45.6%) 24 (48.9%
Non-erosive 20 (42.5%) 19 (41.3%) 20 (40.8%
Erosive 3 (6.4%) 4 (8.7%) 3 (6.1%)
Gastric Ulcer 2 (4.2%) 2 (4.3%) 2 (4.1%)
Duodenitis
Normal 30 (63.8%) 29 (63.1%) 32 (65.3%
Non-erosive 10 (21.3%) 9 (19.5%) 9 (18.3%)
Erosive 2 (4.2%) 3 (6.5%) 2 (4.1%)
Duodenal Ulcer 5 (10.6%) 5 (10.8%) 6 (12.2%)
OMAB = omeprazole, metronidazole, amoxicillin and bismuth subcitrate.
OCA = omeprazole, clarithromycin and amoxicillin.
DM = diabetes mellitus.(Olympus GIF-XQ260, Japan). Two specimens were obtained from
the antrum. Type 2 DM patients were allowed to continue insulin
and oral antidiabetic drugs during the study.
Patients were randomly assigned to one of the two treatment
protocols all given twice daily: (a) a 14-day quadruple therapy
comprising omeprazole 20 mg, metronidazole 500 mg, amoxicillin
1 g and bismuth subcitrate 240 mg (OMAB) and (b) a 14-day triple
regimen comprising omeprazole 20 mg plus clarithromycin
500 mg and amoxicillin 1 g (OCA).
Patients were asked to return at the end of the treatment to as-
sess compliance with therapy that was deﬁned as consumption of
>90% of the prescribed drugs. Medications were discontinued if any
intolerable adverse events such as fever, urticarial rash or general-
ised body pain occurred. Cure was deﬁned as a negative 13C-urea
breath test at least 6 weeks after treatment. HbA1c and fasting
plasma glucose level were measured in all diabetic patients at
the beginning of the study, 3 and 6 months later.
Statistically signiﬁcant differences between groups were as-
sessed using Student’s t-test, chi-squared test as well as Fisher’s
exact test and one-way analysis of variance (ANOVA) test. A p
value of 0.05 or less was considered statistically signiﬁcant. All
the data were analysed using Statistical Package for the Social
Sciences (SPSS) 16 for Windows (SPSS Inc., Chicago, IL, USA)
and the values were expressed as mean ± standard deviation
(SD) for continuous variables and percentages for categorical
variables.
Results
Among 100 patients in each group, 93 type 2 DM (non-insulin
users) and 98 non-diabetic age- and sex-matched patients could
continue the treatment protocols and underwent 13C-urea breath
testing. A total of 191 patients (53.9% male, between 45 andTotal (n = 191) p value
OMAB (n = 49) Control + OCA (n = 49)
) 23 (46.9%) 90 (47.1%) 0.57
) 21 (42.8%) 80 (41.9%) 0.90
2 (4.1%) 12 (6.3%) 0.57
3 (6.1%) 9 (4.7%) 0.23
) 31 (63.2%) 122 (63.9%) 0.90
11 (22.4%) 39 (20.4%) 0.57
2 (4.1%) 9 (4.7%) 0.57
5 (10.2%) 21 (10.9%) 0.23
Table 3
H. pylori eradication ﬁndings of study subjects in different groups.
H. pylori eradication regimens Groups Total (n = 191) p value
DM (n = 93) Control (n = 98)
OMAB 18 of 47 (38.2%) 27 of 49 (55.1%) 45 of 96 (46.8%) <0.001
OCA 29 of 46 (63.0%) 43 0f 49 (87.7%) 72 of 95 (75.7%) 0.017
OMAB = omeprazole, metronidazole, amoxicillin and bismuth subcitrate.
OCA = omeprazole, clarithromycin and amoxicillin.
DM = diabetes mellitus.
Table 4
Effect of H. pylori eradication on the control of glycaemia in patients with type 2 DM.
aCharacter DM Subgroups (n = 93) p value
With H. pylori eradication (n = 47) Without H. pylori eradication (n = 46)
HbA1c decreases (%)
After 3 months 0.23 ± 0.91 0.25 ± 0.85 0.54
After 6 months 0.19 ± 0.85 0.20 ± 0.91 0.77
Fasting plasma glucose decrease (mg dl1)
After 3 months 10.9 ± 12.1 9.5 ± 14.3 0.58
After 6 months 8.9 ± 16.8 9.4 ± 15.6 0.54
HbA1c = glycosylated haemoglobin.
DM = diabetes mellitus.
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jects were studied. There were no statistical differences in the
study groups in age, gender and body mass index (BMI) distribu-
tions (Table 1). Further, no signiﬁcant differences were observed
in HbA1c and fasting plasma glucose between the two diabetic
groups at the beginning of the study.
Upper gastrointestinal endoscopy was performed for all of the
study subjects (Table 2) and there was no signiﬁcant difference
in terms of the rate of gastritis and duodenitis among the four
study groups. As shown in Table 3, H. pylori infection in both
groups (DM and non-DM) was successfully eradicated in 72 of 95
patients (75.7%) with the OCA regimen and in 45 of 96 patients
(46.8%) with the OMAB regimen, respectively (p = 0.003). The H.
pylori eradication rate with the OCA regimen was 63% in patients
with DM and 87.7% in the control group (p = 0.017). The H. pylori
eradication rate with the OMAB regimen was 38.2% in patients
with DM and 55.1% in the control group (p < 0.001).
In patients with type 2 DM, the mean decrease of HbA1c and
fasting plasma glucose level in eradicated cases is similar to non-
eradicated subjects 3 and 6 months after treatment (Table 4).
Discussion
Many researchers have explored the relationship between H.
pylori and DM. There have been controversial results in these stud-
ies but in a large, well-designed study of Xia et al., there was no dif-
ference of the seroprevalence of H. pylori infection between
patients with DM and non-DM controls [5]. Tseng [14] showed a
higher incidence of H. pylori eradication in patients with type 2
DM and in insulin users among the diabetic patients. Further, Poly-
zos [15] studied a potential association between H. pylori infection,
metabolic syndrome and insulin resistance, but further studies are
needed to strengthen this association and to clarify whether there
is a causative link between them.
According to several guidelines, ﬁrst-line standard treatment
for H. pylori eradication consists of triple therapy containing a
PPI, amoxicillin and clarithromycin. In recent decades, the use of
clarithromycin-based treatment and the widespread use of
long-acting macrolides have resulted in considerable resistance
of H. pylori strains to clarithromycin [16]. Standard triple therapy
(omeprazole, clarithromycin and amoxicillin) has been shown tobe effective in the eradication of H. pylori in non-DM subjects
[17,18]. In our control subjects, we found an eradication rate of
87.7%, which was compatible with the results in the literature.
According to the Maastricht III Consensus Report, [19] in pa-
tients with H. pylori infection, the PPI–clarithromycin–amoxicillin
or metronidazole combination is the recommended ﬁrst-choice
treatment in populations with <15–20% clarithromycin resistance
and, in populations with <40% metronidazole resistance, PPI–clar-
ithromycin–metronidazole is preferable. H. pylori infection is usu-
ally eradicated by using multi-drug regimens. Recently, quadruple
drug therapies using a PPI with bismuth triple therapy have been
recommended to decrease the failure rates of H. pylori eradication
caused by resistance to some antibiotics such as metronidazole
and clarithromycin [20].
In the study by Demir et al. [21] of 89 type 2 diabetic patients,
the eradication rate was 51% with standard triple therapy (PPI,
clarithromycin and amoxicillin) and this could be increased by a
quadruple regimen (pantoprazole, bismuth, tetracycline and met-
ronidazole) to 85%. The eradication rate was signiﬁcantly lower
in the DM group than in the non-DM group. However, in our study,
the H. pylori eradication rates were 63% in the OCA-DM group and
38.2% in the OMAB-DM group. Eradication rates in cases (DM and
non-DM) that were administered OMAB treatment were signiﬁ-
cantly lower than in groups with OCA. It seems that low cure rates
following quadruple in our study group can be due to antimicrobial
drug resistance (particularly metronidazole) that is a main source
of treatment failure following these regimens. Broad or inappropri-
ate use of potent antibiotics results in low susceptibility of H. pylori
to some common antibiotics such as metronidazole in our popula-
tion that can lead to development of antibiotic resistance. (In Iran
metronidazole resistance is higher than in Turkey.) In one study, it
has been shown that tetracycline-containing quadruple therapy is
highly effective in treating H. pylori-eradication failures of the
amoxicillin-containing regimen [22]. However, in another study
the results of 14-day tetracycline-containing sequential therapy
for the ﬁrst-line treatment of H. pylori in patients with type 2
DM were disappointing [23]. In a later 7-day trial, all patients re-
ceived pantoprazole 40 mg and amoxicillin 1000 mg twice daily,
followed by pantoprazole 40 mg, metronidazole 500 mg twice dai-
ly and tetracycline 500 mg four times per day for the remaining
7 days.
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eradication rate of H. pylori infection but other mechanisms may
also explain this problem. Type 2 diabetics are more susceptible
to many bacterial infections, which may lead to frequent use of
antibiotics, and to the development of resistance [24]. In our study,
the eradication rate of H. pylori with both OCA and OMAB treat-
ment is lower in patients with type 2 diabetes than in non-
diabetics.
Other factors that might inﬂuence the H. pylori eradication rate
are diabetes duration, glycaemic level, obesity, being on oral hypo-
glycaemics or insulin and socioeconomic status. In Tseng’s study,
[14] a signiﬁcantly higher incidence of H. pylori eradication in pa-
tients with type 2DM and in insulin users was seen. The odds ratios
were attenuated with increasing diabetes duration, probably due
to the occurrence of other co-morbidities. Additionally, lower
socioeconomic status and the use of calcium channel blockers con-
sistently show a higher rate of H. pylori eradication, but the uses of
oral anti-diabetic agents do not. Although data seem to indicate an
association between H. pylori infection and insulin resistance, fur-
ther studies are needed to clarify whether there is a causative link
between them. If a causal link is conﬁrmed, this may have a major
impact on the pathophysiology and management of insulin resis-
tance syndrome, including type 2 DM and non-alcoholic fatty liver
disease [15].
Toussy et al. [25] showed that the mean decrease of HbA1c level
after 3 months in the case (treatment) group is more than in the
control (without treatment) group; however, this difference is
not statistically signiﬁcant and very small. In our patients with
type 2 DM, the mean decrease of HbA1c and fasting plasma glucose
level in eradicated cases is similar to non-eradicated subjects 3 and
6 months after treatment. Thus, it suggests that H. pylori treatment
in patients with type 2 DM has no role in control of the disease.
In conclusion, we found that the eradication rate of H. pylori
with OCA or OMAB treatment is lower in patients with type 2 dia-
betes than in non-diabetics and H. pylori treatment in patients with
type 2 DM has no role in control of the glycaemia. The superiority
of 2-week triple therapy to 2-week quadruple protocol can be due
to the low susceptibility of H. pylori to administered drugs such as
metronidazole in the second regimen and also low resistance of
used antibiotics such as clarithromycin in triple therapy in the Ira-
nian population. Further studies with new antibiotic combinations
are needed to ﬁnd better methods of eradicating H. pylori in pa-
tients with type 2 DM.
Acknowledgements
The study was supported by the Shahid Beheshti and Golestan
University of Medical Sciences. We wish to thank all the research-
ers who took part in this research project in Research Center for
Gastroenterology and Liver Disease (RCGLD) and Golestan Re-
search Center of Gastroenterology & Hepatology (GRCGH).
References
[1] Kaufman FR. Diabetes mellitus. Pediatr Rev 1997;18(11):383–92. Quiz 393.
[2] Candelli M, Rigante D, Marietti G, et al. Helicobacter pylori, gastrointestinal
symptoms and metabolic control in young type 1 diabetes mellitus patients.
Pediatrics 2003;111(4):800–3.[3] Begue RE, Mirza A, Compton T, et al. Helicobacter pylori infection and insulin
requirement among children with type 1 diabetes mellitus. Pediatrics
1999;103(6):e83.
[4] Sargy´n M, Uygur-Bayramiçli O, Sargy´n H, et al. Type 2 diabetes mellitus affects
eradication rate of Helicobacter pylori. World J Gastroenterol
2003;9(5):1126–8.
[5] Xia HHN, Talley NJ, Kam EPY, et al. Helicobacter pylori infection is not
associated with diabetes mellitus, nor with upper gastrointestinal symptoms
in diabetes mellitus. Am J Gastroenterol 2001;96(4):1039–46.
[6] Uygur-Bayramiçli O, Kiliç D, Yavuzer D, et al. Helicobacter pylori colonization
and immunological disease. Eur J Gastroenterol Hepatol 2001;13(3):301–2.
[7] Demir M, Gokturk HS, Ozturk NA, et al. Efﬁcacy of two different Helicobacter
pylori eradication regimens in patients with type 2 diabetes and the effect of
Helicobacter pylori eradication on dyspeptic symptoms in patients with
diabetes: a randomized controlled study. Am J Med Sci 2009;338(6):459–64.
[8] Gené E, Calvet X, Azagra R, et al. Triple vs. quadruple therapy for treating
Helicobacter pylori infection: a meta-analysis. Alimen Pharmacol Therap
2003;17(9):1137–43.
[9] Katelaris PH, Forbes GM, Talley NJ, et al. A randomized comparison of
quadruple and triple therapies for Helicobacter pylori eradication: the
QUADRATE study. Gastroenterology 2002;123(6):1763–9.
[10] Laine L, Hunt R, EI-Zimaity H, et al. Bismuth-based quadruple therapy using a
single capsule of bismuth biskalcitrate, metronidazole and tetracycline given
with omeprazole versus omeprazole, amoxicillin and clarithromycin for
eradication of Helicobacter pylori in duodenal ulcer patients: a prospective,
randomized, multicenter, North American trial. Am J Gastroenterol
2003;98(3):562–7.
[11] Laine L. Is it time for quadruple therapy to be ﬁrst line? In: Laine L, editor.
Helicobacter pylori: Basic mechanisms to clinical cure. Dordrecht: Kluwer
Academic Publishers; 2002. p. 347–51.
[12] Calvet X, Ducons J, Guardiola J, et al. One-week triple vs. quadruple therapy for
Helicobacter pylori infection - a randomized trial. Alimen Pharmacol Therap
2002;16(7):1261–7.
[13] Gomollón F, Valdepérez J, Garuz R, et al. Analisis coste-efectividad de dos
estrategias de erradicacion de Helicobacter pylori: Resultados de un estudio
prospectivo y aleatorizado en atencion primaria [Cost/effectiveness analysis of
two strategies for Helicobacter pylori eradication: Results of a prospective and
randomized study in primary care setting]. Med Clin 2000;115(1):1–6.
[14] Tseng CH. Diabetes, insulin use and Helicobacter pylori eradication: a
retrospective cohort study. BMC Gastroenterol 2012;12. Art. No. 46.
[15] Polyzos SA, Kountouras J, Zavos C, et al. The association between Helicobacter
pylori infection and insulin resistance: a systematic review. Helicobacter
2011;16(2):79–88.
[16] Seyyedmajidi M, Falaknazi K, Mirsattari D, et al. Correlation between
creatinine clearance and Helicobacter pylori infection eradication with
sequential and triple therapeutic regimens: a randomised clinical trial. Arab
J Gastroenterol 2011;12(3):150–3.
[17] Wurzer H, Rodrigo L, Stamler D, et al. Short-course therapy with Amoxycillin-
Clarithormycin Triple therapy for 10 days (ACT-10) eradicates Helicobacter
pylori and heals duodenal ulcer. Alimen Pharmacol Therap
1997;11(5):943–52.
[18] Viara D, Ali A, Gatta L, et al. Treatment of Helicobacter pylori. Curr Opin
Gastroenterol 1998;14(Suppl. 1):71–8.
[19] Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the
management of Helicobacter pylori infection: the maastricht III consensus
report. Gut 2007;56(6):772–81.
[20] Uygun A, Kadayifci A, Safali M, et al. The efﬁcacy of bismuth containing
quadruple therapy as a ﬁrst-line treatment option for Helicobacter pylori. J Dig
Dis 2007;8(4):211–5.
[21] Demir M, Göktürk S, Öztürk NA, et al. Bismuth-based ﬁrst-line therapy for
Helicobacter pylori eradication in type 2 diabetes mellitus patients. Digestion
2010;82(1):47–53.
[22] Georgopoulos SD, Ladas SD, Karatapanis S, et al. Effectiveness of two
quadruple, tetracycline- or clarithromycin-containing, second-line,
Helicobacter pylori eradication therapies. Alimen Pharmacol Therap
2002;16(3):569–75.
[23] Ataseven H, Demir M, Gen R. Effect of sequential treatment as a ﬁrst-line
therapy for Helicobacter pylori eradication in patients with diabetes mellitus.
South Med J 2010;103(10):988–92.
[24] Van Zwet AA, Mégraud F. Diagnosis. Curr Opin Gastroenterol 1998;14(Suppl.
1). S27-33.
[25] Moghimi J, Toussy J, Babaei M, et al. Effect of Helicobacter pylori eradication on
short-term control of glycemia in patients with type 2 diabetes mellitus. Saudi
Med J 2007;28(3):475–6.
